Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

Trial Profile

Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ibuprofen (Primary) ; Sodium cromoglicate (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms COGNITE
  • Sponsors AZTherapies
  • Most Recent Events

    • 15 Sep 2015 According to AZTherapies media release, company has received a SPA agreement with the FDA for this trial.
    • 29 May 2014 Interim data are expected in the first half of 2016, and trial completion and the final data report are expected in the first half of 2017, according to the AZTherapeutics website.
    • 29 May 2014 This trial is expected to be initiated by quarter 4, 2014, according to an AZTherapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top